Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

SELL
$76.68 - $93.31 $10,735 - $13,063
-140 Reduced 3.8%
3,543 $322,000
Q1 2023

May 12, 2023

BUY
$46.59 - $66.96 $171,590 - $246,613
3,683 New
3,683 $242,000
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $158,584 - $246,805
3,543 New
3,543 $242,000
Q3 2021

Nov 15, 2021

SELL
$31.4 - $69.84 $111,250 - $247,443
-3,543 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $144,908 - $229,940
3,543 New
3,543 $224,000
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $144,554 - $203,332
-3,543 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$30.79 - $57.2 $109,088 - $202,659
3,543 New
3,543 $203,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.65B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Veritable, L.P. Portfolio

Follow Veritable, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Veritable, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Veritable, L.P. with notifications on news.